IGC Pharma Statistics
Total Valuation
IGC Pharma has a market cap or net worth of $32.61 million. The enterprise value is $31.29 million.
| Market Cap | 32.61M |
| Enterprise Value | 31.29M |
Important Dates
The last earnings date was Wednesday, February 14, 2024, after market close.
| Earnings Date | Feb 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
IGC Pharma has 66.54 million shares outstanding. The number of shares has increased by 20.09% in one year.
| Shares Outstanding | 66.54M |
| Shares Change (YoY) | +20.09% |
| Shares Change (QoQ) | +17.36% |
| Owned by Insiders (%) | 20.44% |
| Owned by Institutions (%) | 3.71% |
| Float | 56.96M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 26.81 |
| Forward PS | 23.48 |
| PB Ratio | 3.60 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 25.73 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.85, with a Debt / Equity ratio of 0.03.
| Current Ratio | 1.85 |
| Quick Ratio | 0.86 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -110.40% and return on invested capital (ROIC) is -125.37%.
| Return on Equity (ROE) | -110.40% |
| Return on Assets (ROA) | -93.30% |
| Return on Capital (ROIC) | -125.37% |
| Revenue Per Employee | $19,934 |
| Profits Per Employee | -$231,885 |
| Employee Count | 61 |
| Asset Turnover | 0.08 |
| Inventory Turnover | 0.21 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +38.42% in the last 52 weeks. The beta is 1.77, so IGC Pharma's price volatility has been higher than the market average.
| Beta (1Y) | 1.77 |
| 52-Week Price Change | +38.42% |
| 50-Day Moving Average | 0.40 |
| 200-Day Moving Average | 0.34 |
| Relative Strength Index (RSI) | 51.73 |
| Average Volume (30 Days) | 956,667 |
Short Selling Information
The latest short interest is 938,802, so 1.41% of the outstanding shares have been sold short.
| Short Interest | 938,802 |
| Short Previous Month | 910,725 |
| Short % of Shares Out | 1.41% |
| Short % of Float | 1.65% |
| Short Ratio (days to cover) | 1.25 |
Income Statement
In the last 12 months, IGC Pharma had revenue of $1.22 million and -$14.15 million in losses. Loss per share was -$0.26.
| Revenue | 1.22M |
| Gross Profit | 625,000 |
| Operating Income | -11.67M |
| Pretax Income | -14.15M |
| Net Income | -14.15M |
| EBITDA | -13.52M |
| EBIT | -14.15M |
| Loss Per Share | -$0.26 |
Balance Sheet
The company has $1.57 million in cash and $253,000 in debt, giving a net cash position of $1.31 million or $0.02 per share.
| Cash & Cash Equivalents | 1.57M |
| Total Debt | 253,000 |
| Net Cash | 1.31M |
| Net Cash Per Share | $0.02 |
| Equity / Book Value | 9.05M |
| Book Value Per Share | 0.14 |
| Working Capital | 1.65M |
Cash Flow
In the last 12 months, operating cash flow was -$6.19 million and capital expenditures -$92,000, giving a free cash flow of -$6.28 million.
| Operating Cash Flow | -6.19M |
| Capital Expenditures | -92,000 |
| Free Cash Flow | -6.28M |
| FCF Per Share | -$0.10 |
Margins
Gross margin is 51.40%, with operating and profit margins of -959.46% and -1,163.24%.
| Gross Margin | 51.40% |
| Operating Margin | -959.46% |
| Pretax Margin | -1,163.24% |
| Profit Margin | -1,163.24% |
| EBITDA Margin | -1,111.76% |
| EBIT Margin | -1,163.24% |
| FCF Margin | -516.61% |
Dividends & Yields
IGC Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -20.09% |
| Shareholder Yield | -20.09% |
| Earnings Yield | -43.38% |
| FCF Yield | -19.27% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on April 19, 2013. It was a reverse split with a ratio of 1:10.
| Last Split Date | Apr 19, 2013 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
IGC Pharma has an Altman Z-Score of -8.77 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.77 |
| Piotroski F-Score | 3 |